IN2015DN04172A - - Google Patents

Info

Publication number: IN2015DN04172A
Authority: IN; India
Prior art keywords: lateral sclerosis; amyotrophic lateral; individual; therapeutic agent; ghs
Prior art date: 2012-10-24

Application number

Other languages

English (en)

Inventor

Tsuyoshi Matsuo

Norihito Murayama

Mayumi Furuya

Original Assignee

Daiichi Sankyo Companyltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-10-24

Filing date

2013-10-23

Publication date

2015-10-16

2013-10-23 Application filed by Daiichi Sankyo Companyltd filed Critical Daiichi Sankyo Companyltd

2015-10-16 Publication of IN2015DN04172A publication Critical patent/IN2015DN04172A/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Neurology (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Cell Biology (AREA)
Marine Sciences & Fisheries (AREA)

IN4172DEN2015 2012-10-24 2013-10-23 IN2015DN04172A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2012234300		2012-10-24
PCT/JP2013/078743 WO2014065341A1 (fr)	2012-10-24	2013-10-23	Agent thérapeutique pour la sclérose latérale amyotrophique

Publications (1)

Publication Number	Publication Date
IN2015DN04172A true IN2015DN04172A (fr)	2015-10-16

Family

ID=50544716

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN4172DEN2015 IN2015DN04172A (fr)	2012-10-24	2013-10-23

Country Status (11)

Country	Link
US (1)	US20150265680A1 (fr)
EP (1)	EP2913063B1 (fr)
JP (1)	JP6262661B2 (fr)
KR (3)	KR20150070180A (fr)
CN (2)	CN110354265A (fr)
AU (1)	AU2013335678B9 (fr)
BR (1)	BR112015009107A2 (fr)
CA (1)	CA2889499C (fr)
IN (1)	IN2015DN04172A (fr)
RU (1)	RU2655811C2 (fr)
WO (1)	WO2014065341A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2017533951A (ja)	2014-11-12	2017-11-16	リリック・ファーマシューティカルズ・インコーポレイテッドＬｙｒｉｃＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃ．	経腸栄養不耐性の処置
WO2017083882A1 (fr) *	2015-11-11	2017-05-18	Lyric Pharmaceuticals Inc.	Traitement de l'intolérance à l'alimentation entérale et d'autres troubles à l'aide d'analogues d'ulimoréline
MA54383A (fr) *	2018-12-06	2021-10-13	Biogen Ma Inc	Protéine neurofilamenteuse pour guider une intervention thérapeutique dans la sclérose laterale amyotrophique
US11969416B1 (en)	2022-11-03	2024-04-30	Lumos Pharma, Inc.	Compactable oral formulations of ibutamoren

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5668254A (en)	1990-05-11	1997-09-16	Romano Deghenghi	D-2-alkyl-tryptophan and peptides containing same
US5663146A (en)	1991-08-22	1997-09-02	Administrators Of The Tulane Educational Fund	Polypeptide analogues having growth hormone releasing activity
US5536716A (en)	1992-12-11	1996-07-16	Merck & Co., Inc.	Spiro piperidines and homologs which promote release of growth hormone
TW432073B (en)	1995-12-28	2001-05-01	Pfizer	Pyrazolopyridine compounds
CN1161333C (zh)	1998-08-20	2004-08-11	住友制药株式会社	作为生长激素释放剂的2-羟基吲哚衍生物
CA2696819C (fr) *	1999-07-23	2015-07-07	Kenji Kangawa	Peptides apparentes a la ghreline
UA73530C2 (uk)	1999-11-10	2005-08-15	Ново Нордіск А/С	Сполука з властивостями вивільнювати гормон росту
DE60022683D1 (de) *	1999-12-28	2005-10-20	Kaken Pharma Co Ltd	Nervenschutzmittel
PT1524272E (pt)	2000-06-13	2007-07-25	Aeterna Zentaris Gmbh	Secretagogos de hormona de crescimento
CN100491395C (zh)	2002-04-11	2009-05-27	阿斯比奥制药株式会社	修饰肽的制造方法
US7476653B2 (en)	2003-06-18	2009-01-13	Tranzyme Pharma, Inc.	Macrocyclic modulators of the ghrelin receptor
JP2005239712A (ja)	2004-01-30	2005-09-08	Kaken Pharmaceut Co Ltd	神経突起伸展剤
WO2006079077A2 (fr) *	2005-01-20	2006-07-27	Acadia Pharmaceuticals Inc.	Composes en tant que modulateurs de recepteur de ghreline et leurs utilisations
US7829589B2 (en)	2005-06-10	2010-11-09	Elixir Pharmaceuticals, Inc.	Sulfonamide compounds and uses thereof
KR20080066014A (ko) *	2005-10-18	2008-07-15	오노 야꾸힝 고교 가부시키가이샤	근위축성측삭경화증 환자의 운동 신경 보호용 의약
CA2654292C (fr)	2006-06-07	2022-01-11	Genzyme Corporation	Therapie genique pour les maladies des motoneurones
JP2008127377A (ja)	2006-11-24	2008-06-05	Jichi Medical Univ	Ｇｈｓ−ｒ作動薬を含有してなるメタボリックシンドローム又は高血圧症の予防・治療剤。
KR100946084B1 (ko)	2008-03-27	2010-03-10	주식회사 하이닉스반도체	반도체 소자의 수직형 트랜지스터 및 그 형성방법
CA2720408C (fr) *	2008-04-03	2016-09-06	F. Hoffmann-La Roche Ag	Utilisation de variants de igf-i pegyles pour traiter des troubles neuromusculaires

2013
- 2013-10-23 CN CN201910808882.7A patent/CN110354265A/zh active Pending
- 2013-10-23 JP JP2014543332A patent/JP6262661B2/ja active Active
- 2013-10-23 AU AU2013335678A patent/AU2013335678B9/en active Active
- 2013-10-23 RU RU2015119472A patent/RU2655811C2/ru active
- 2013-10-23 US US14/437,459 patent/US20150265680A1/en not_active Abandoned
- 2013-10-23 CN CN201380066625.1A patent/CN104853778A/zh active Pending
- 2013-10-23 WO PCT/JP2013/078743 patent/WO2014065341A1/fr active Application Filing
- 2013-10-23 CA CA2889499A patent/CA2889499C/fr active Active
- 2013-10-23 KR KR1020157010085A patent/KR20150070180A/ko not_active Ceased
- 2013-10-23 BR BR112015009107A patent/BR112015009107A2/pt not_active Application Discontinuation
- 2013-10-23 KR KR1020207026038A patent/KR20200108494A/ko not_active Withdrawn
- 2013-10-23 EP EP13848825.9A patent/EP2913063B1/fr active Active
- 2013-10-23 IN IN4172DEN2015 patent/IN2015DN04172A/en unknown
- 2013-10-23 KR KR1020227012378A patent/KR102499918B1/ko active Active

Also Published As

Publication number	Publication date
JP6262661B2 (ja)	2018-01-17
BR112015009107A2 (pt)	2017-11-14
KR20150070180A (ko)	2015-06-24
HK1214152A1 (en)	2016-07-22
RU2655811C2 (ru)	2018-05-29
CA2889499A1 (fr)	2014-05-01
KR102499918B1 (ko)	2023-02-14
AU2013335678A1 (en)	2015-05-21
CN104853778A (zh)	2015-08-19
KR20200108494A (ko)	2020-09-18
RU2015119472A (ru)	2016-12-20
KR20220051418A (ko)	2022-04-26
WO2014065341A1 (fr)	2014-05-01
CA2889499C (fr)	2019-09-10
EP2913063B1 (fr)	2019-09-11
EP2913063A1 (fr)	2015-09-02
CN110354265A (zh)	2019-10-22
EP2913063A4 (fr)	2016-07-20
JPWO2014065341A1 (ja)	2016-09-08
AU2013335678B2 (en)	2017-10-26
AU2013335678B9 (en)	2024-12-12
US20150265680A1 (en)	2015-09-24

Publication	Publication Date	Title
Panlilio et al.	2013	Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction
PH12013501244A1 (en)	2013-07-15	A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
MX2022007975A (es)	2022-07-05	Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrogenos y usos de los mismos.
MX2014011353A (es)	2014-12-05	Inmunomodulacion de compuestos ciclicos del bucle bc de muerte celular programada (pd1) humana.
PH12014502516A1 (en)	2015-01-12	Formulations and methods for vaginal delivery of antiprogestins
IN2015KN00414A (fr)	2015-07-17
EA201270221A1 (ru)	2012-08-30	Лечение болезни крона с применением лаквинимода
PH12014500472A1 (en)	2014-05-12	Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
IN2015DN01815A (fr)	2015-05-29
PH12012501480A1 (en)	2012-10-22	Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PH12014500239A1 (en)	2014-03-31	Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX341482B (es)	2016-08-22	Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23.
WO2011157416A3 (fr)	2012-06-07	Administration transdermique de mémantine
PH12017502049A1 (en)	2018-08-29	Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
NZ745853A (en)	2025-05-02	Methods of treating depression using orexin-2 receptor antagonists
IN2014DN05869A (fr)	2015-05-22
IN2015DN04172A (fr)	2015-10-16
HK1223825A1 (zh)	2017-08-11	包含阿曲生坦的穩定化藥物劑型
HK1203394A1 (en)	2015-10-30	Ghrelin receptor agonists for the treatment of achlorhydria
MX2016006657A (es)	2016-10-12	Antagonistas de gastrina (por ejemplo, yf476, netazepido) para el tratamiento y prevencion de osteoporosis.
SG10201809506TA (en)	2018-11-29	Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
AU2018279669A8 (en)	2020-10-15	Carboxylic acid derivative as at AT2R receptor antagonist
MX2014014817A (es)	2015-02-12	Compuestos para el tratamiento de inflamacion y dolor.
MY198069A (en)	2023-07-31	Method for preventing or treating autism spectrum disorders by benzoic acid salt
MX2014014813A (es)	2015-02-12	Uso de agonistas o antagonistas inversos para el receptor de grelina para tratar trastornos del sueño.